The generally available targeted drugs for bowel adenocarcinoma combined with liver metastasis are cetuximab and so on. The most common metastatic organ of colorectal cancer is liver, which is also one of the main causes of death in advanced colorectal cancer. Bowel adenocarcinoma combined with liver metastasis indicates that the bowel cancer has entered the advanced stage, at this time, the chance of surgery has usually been lost, and comprehensive treatment is usually recommended. Targeted therapy drugs are mainly: 1. cetuximab, a human-mouse chimeric monoclonal antibody against EGFR, is used in combination with chemotherapy for the treatment of metastatic colorectal cancer with wild-type RAS gene; 2. bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor receptor (VEGF), combined with chemotherapy has good effect as the first-line treatment for liver metastasis of unresectable colorectal cancer; 3. regorafenib, an oral multi-targeted tyrosine kinase inhibitor (TKI) that blocks several pro-angiogenic VEGFRs, inhibits the activity of multiple kinases associated with tumorigenesis and the tumor microenvironment; 4. furaquintinib, an oral tyrosine kinase inhibitor (TKI) that highly selectively inhibits all three subtypes of the VEGF receptor 1, 2 and 3. Furaquintinib can inhibit VEGF receptor phosphorylation, thereby inhibiting tumor angiogenesis and ultimately inhibiting tumor growth. It is recommended to go to regular hospitals for consultation and treatment, and follow the doctor’s instructions to cooperate with the treatment, so as not to delay the condition. Drug therapy has specific indications, dosage, and the possibility of adverse reactions, please strictly follow the doctor’s instructions, do not self-medication.